Small-cap stocks clung to the lower reaches of the broader market Thursday, largely moving in sync with the lukewarm

Dow Jones Industrial Average

.

Weighing things down were several health stocks, among them

Progen Pharmaceuticals

(PGLA)

, an Australia-based biotech that agreed to sell 6.9 million of its shares to institutional and other investors for a heavily discounted price of $4.75 apiece. Shares were plunging 19.9% to $4.83 in recent trading.

Monogram Biosciences

( MGRM) lost a penny more than the Street had expected, according to Thomson Financial, and came in under sales estimates. Shares of the diagnostic-substances maker lost 11.4% to $1.64.

Fellow Californian

Clarient

( CLRT), purveyor of cancer-related diagnostic services, sank 13.2% to $2.10 after posting a first-quarter continuing-operations loss of 6 cents a share that missed two analysts' estimates by 2 cents.

Meanwhile, medical-products maker

Thoratec

(THOR) - Get Report

, of Pleasanton, Calif., plunged 14.5% to $17.01 despite edging out top- and bottom-line estimates for the first quarter.

Town Sports International

(CLUB) - Get Report

, a New York-based fitness-club operator, was off 9.4% to $20.54 after widening its GAAP-based first-quarter loss.

Small tech losers included semiconductor-equipment maker

Axcelis Technologies

(ACLS) - Get Report

, which reported first-quarter income that fell just under the Street's 4-cent-per-share targets, and

Optelecom-NKF

( OPTC), a communications-equipment maker that swung to a first-quarter loss vs. last year. Axcelis, based in Beverly, Mass., plummeted 19.2% to $6.63. Maryland-based Optelecom tumbled 19.8% to $6.71.

On the other hand, California-based

Hansen Medical

(HNSN)

shot up more than 20% to $22.75 after the Food and Drug Administration approved for commercialization its Sensei Robotic Catheter System and Artisan Control Catheter, a platform that assists physicians during the diagnostic phase of complex cardiac arrhythmia treatment.

EpiCept

( EPCT) said a midphase trial of its NP-1 cream pain medication achieved its primary endpoint in patients with a painful condition called post-herpetic neuralgia. Shares of the Tarrytown, N.Y., company were leaping 11% to $3.24.

Another health name,

Albany Molecular Research

(AMRI)

vaulted 11.7% to $10.73 after first-quarter income totaled a dime a share vs. 6 cents a year ago. Analysts were looking for profits to flat-line with last year.

Also coming in higher than anticipated were staffing-services firm

Hudson Highland

( HHGP), recently leaping 12.2% to $18.99; wireless-products maker

Ntelos

(NTLS)

, which added 9.4% to $22.21; and

PGT

(PGTI) - Get Report

, maker of impact-resistant windows and doors, lately up 13.3% to $11.90.

The Russell 2000 and

S&P

SmallCap 600 indices were both up slightly.